Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
250
-
Total 13F shares, excl. options
-
84M
-
Shares change
-
-923K
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
-$9.96M
-
Put/Call ratio
-
0.36
-
Number of buys
-
145
-
Number of sells
-
-98
-
Price
-
$18.60
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2022
281 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2022.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 250 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84M shares
of 123M outstanding shares and own 68.21% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15.7M shares), STATE STREET CORP (7.87M shares), VANGUARD GROUP INC (6.77M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (5.88M shares), MILLENNIUM MANAGEMENT LLC (2.31M shares), DIMENSIONAL FUND ADVISORS LP (2.31M shares), TWO SIGMA INVESTMENTS, LP (1.93M shares), TWO SIGMA ADVISERS, LP (1.81M shares), GEODE CAPITAL MANAGEMENT, LLC (1.76M shares), and MORGAN STANLEY (1.74M shares).
This table shows the top 250 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.